GLP1R and diabetic kidney disease: Current DKD management integrates lifestyle modifications with four cornerstone pharmacologic classes: renin–angiotensin–aldosterone system inhibitors (RAASi), sodium–glucose co-transporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and mineralocorticoid receptor antagonists (MRAs).